Cargando…

CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis

The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French...

Descripción completa

Detalles Bibliográficos
Autores principales: Pépin, Jean-Louis, Bailly, Sébastien, Rinder, Pierre, Adler, Dan, Szeftel, Daniel, Malhotra, Atul, Cistulli, Peter A., Benjafield, Adam, Lavergne, Florent, Josseran, Anne, Tamisier, Renaud, Hornus, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957656/
https://www.ncbi.nlm.nih.gov/pubmed/33804319
http://dx.doi.org/10.3390/jcm10050936
_version_ 1783664699111374848
author Pépin, Jean-Louis
Bailly, Sébastien
Rinder, Pierre
Adler, Dan
Szeftel, Daniel
Malhotra, Atul
Cistulli, Peter A.
Benjafield, Adam
Lavergne, Florent
Josseran, Anne
Tamisier, Renaud
Hornus, Pierre
author_facet Pépin, Jean-Louis
Bailly, Sébastien
Rinder, Pierre
Adler, Dan
Szeftel, Daniel
Malhotra, Atul
Cistulli, Peter A.
Benjafield, Adam
Lavergne, Florent
Josseran, Anne
Tamisier, Renaud
Hornus, Pierre
author_sort Pépin, Jean-Louis
collection PubMed
description The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA.
format Online
Article
Text
id pubmed-7957656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79576562021-03-16 CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis Pépin, Jean-Louis Bailly, Sébastien Rinder, Pierre Adler, Dan Szeftel, Daniel Malhotra, Atul Cistulli, Peter A. Benjafield, Adam Lavergne, Florent Josseran, Anne Tamisier, Renaud Hornus, Pierre J Clin Med Article The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA. MDPI 2021-03-01 /pmc/articles/PMC7957656/ /pubmed/33804319 http://dx.doi.org/10.3390/jcm10050936 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pépin, Jean-Louis
Bailly, Sébastien
Rinder, Pierre
Adler, Dan
Szeftel, Daniel
Malhotra, Atul
Cistulli, Peter A.
Benjafield, Adam
Lavergne, Florent
Josseran, Anne
Tamisier, Renaud
Hornus, Pierre
CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title_full CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title_fullStr CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title_full_unstemmed CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title_short CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
title_sort cpap therapy termination rates by osa phenotype: a french nationwide database analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957656/
https://www.ncbi.nlm.nih.gov/pubmed/33804319
http://dx.doi.org/10.3390/jcm10050936
work_keys_str_mv AT pepinjeanlouis cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT baillysebastien cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT rinderpierre cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT adlerdan cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT szefteldaniel cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT malhotraatul cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT cistullipetera cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT benjafieldadam cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT lavergneflorent cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT josserananne cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT tamisierrenaud cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT hornuspierre cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis
AT cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis